FDA Grants Orphan Drug Designation to Zenocutuzumab‑zbco for NRG1+ CCA The FDA has granted Orphan Drug Designation to zenocutuzumab-zbco (Bizengri) for advanced NRG1 fusion-positive cholangiocarcinoma (CCA).

The @fda.gov has granted #OrphanDrug Designation to zenocutuzumab-zbco (#Bizengri®) for adults with advanced unresectable or metastatic neuregulin 1 (#NRG1) gene fusion-positive #Cholangiocarcinoma (#CCA), according to a recent press release.

Read here: https://bit.ly/4apGNlR

#RareDisease #MedSky

Significant Benefits of Zenocutuzumab in Treatment-Resistant Pancreatic and Cholangiocarcinoma Patients Recent findings from the eNRGy trial suggest that continuing zenocutuzumab treatment after disease progression can greatly benefit patients with NRG1+ pancreatic cancer and cholangiocarcinoma.

Significant Benefits of Zenocutuzumab in Treatment-Resistant Pancreatic and Cholangiocarcinoma Patients #United_States #San_Francisco #Cancer_Treatment #Zenocutuzumab #NRG1

NRG1 Fusions Across Solid Tumors: Detection Strategies and Distinct Clinical Features in Pancreatic Cancer - OncoDaily NRG1 Fusions Across Solid Tumors: Detection Strategies and Distinct Clinical Features in Pancreatic Cancer / cancer, cancer care, Cancer research, cancer

NRG1 Fusions Across Solid Tumors: Detection Strategies and Distinct Clinical Features in Pancreatic Cancer

oncodaily.com/opinion/nrg1...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NRG1 #PancreaticCancer #SolidTumors

Promising Efficacy of Zenocutuzumab in Treatment-Naïve NRG1+ NSCLC Patients Discussed at IASLC-ASCO NACLC Recent findings on zenocutuzumab-zbco reveal durable efficacy in treatment-naïve NRG1+ non-small cell lung cancer, showcasing impactful results from the eNRGy trial.

Promising Efficacy of Zenocutuzumab in Treatment-Naïve NRG1+ NSCLC Patients Discussed at IASLC-ASCO NACLC #NSCLC #company_number #BIZENGRI #NRG1

FDA Grants Breakthrough Therapy Status to Zenocutuzumab-zbco for Challenging Cholangiocarcinoma Treatment The FDA has assigned a Breakthrough Therapy designation to zenocutuzumab-zbco aimed at treating NRG1-positive cholangiocarcinoma, highlighting promising interim trial results.

FDA Grants Breakthrough Therapy Status to Zenocutuzumab-zbco for Challenging Cholangiocarcinoma Treatment #USA #Lexington #Zenocutuzumab #Cholangiocarcinoma #NRG1

Amazing presentation of Dr. @ADesaiMD about NTRK (Neurotrophic Tyrosine Receptor Kinase).

Join us now at live.classy.org/register/ttl...

#MET #NTRK #NRG1 #NSCLC

Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer | NEJM Neuregulin 1 (NRG1) fusions are recurrent oncogenic drivers found in multiple solid tumors. NRG1 binds to human epidermal growth factor receptor 3 (HER3), leading to heterodimerization with HER2 an...

Results from the phase II study of zenocutuzumab in #NRG1 fusion+ cancers now @nejm.org. RR 30% with DOR 11.1m, PFS 6.8m, favorable safety profile. NRG1+ lung cancers do not respond well to standard therapy. Zenocutuzumab now FDA approved for NSCLC, pancreatic cancer.

www.nejm.org/doi/full/10....

addressing the rare #NRG1 fusion! Especially working well in #KRAS wildtype #pancreaticcancer

NEW 🚨: The @fda.gov has granted accelerated approval to #zenocutuzumab for treating patients with advanced #pancreaticcancer or non-small cell #lungcancer that has an alteration called an #NRG1 gene fusion and whose disease progressed after other treatments.

ICYMI in Cancer Discovery: Zenocutuzumab, a #HER2 x #HER3 #Bispecific Antibody, Is Effective Therapy for Tumors Driven by #NRG1 Gene Rearrangements - by Alison Schram and colleagues @mskcancercenter.bsky.social doi.org/10.1158/2159...

FDA grants accelerated approval to zenocutuzumab-zbco On December 4, 2024, the FDA granted accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma.

#FDA grants accelerated approval to HER2/HER3 bispecific ab
#zenocutuzumab for previously treated advanced #NSCLC and #pancreatic cancer and #NRG1 fusion. Thanks to patients, PIs (Ali Schram, Alex Drilon, Jordi Rodon, Eileen O'Reilly, and others) #OncSky #MedSky
www.fda.gov/drugs/resour...

FDA grants accelerated approval to zenocutuzumab-zbco On December 4, 2024, the FDA granted accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma.

Zenocutuzumab, a HER2/3 bispecific, now approved for #NRG1 fusion positive NSCLC and pancreatic cancers. Best to use RNA-seq to find this fusion - DNA based NGS often misses it. Outcomes poor with standard therapy - this is an an important approval. #OncSky #LCSM

www.fda.gov/drugs/resour...